Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2001-03-02
2003-04-15
Solola, Taofiq (Department: 1626)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C549S456000
Reexamination Certificate
active
06548537
ABSTRACT:
FIELD OF THE INVENTION
The present invention relates to compounds useful as immunosuppressive, anti-inflammatory and anticancer agents. The compounds have good aqueous solubility and convert to biologically active compounds in vivo.
REFERENCES
Boyd, G. V. and Heatherington, K.,
J. Chem. Soc. Perkin I
2523-2531 (1973).
Ferrier, R. J., in
Carbohydrate Chemistry,
Kennedy, J. F., Ed., Clarendon Press, Oxford (1990).
Garver, L. C. et al.,
J. Am. Chem. Soc.
104:867 (1982).
Gleichmann, E. et al.,
Immunol. Today
5:324 (1984).
Hormi, O. E. O. and Nasman, J. H.,
Syn. Commun.
16:69 (1986).
Kocienski, P. J.,
Protecting Groups,
Georg Thieme Verlag, Stuttgart (1994).
Korngold, R. and Sprent, J.,
J. Exp. Med.
148:1687 (1978).
Kupchan, S. M. et al.,
J. Am. Chem. Soc.
94:7194 (1972).
Kupchan, S. M. et al., U.S. Pat. No. 3,005,108 (1977).
Lipsky, P. E. et al., U.S. Pat. No. 5,294,443 (1994).
Ma, P-C. et al.,
J. Chin. Pharm. Sci.
1:12 (1992).
Mori, S. et al.,
Tetrahedron
47(27):5051-5070 (1991).
Morris, R. E.,
Transplant Proc.
23(6):2722-2724 (1991).
Morris, R. E. et al.,
Transplant Proc.
23(1):238-240 (1991).
Murase, N. et al.,
Transplantation
55:701 (1993).
Ono and Lindsey,
J. Thor. Cardiovasc. Surg.
57(2):225-29 (1969).
Pu, L. et al.,
Zhongguo Yaoli Xuebao
11:76 (1990).
Wang, J. and Morris, R. E.,
Transplantation Proc.
23:699 (1991).
Yu et al.,
Acta Pharmaceutica Sinica
27(11):830-836 (1992).
Zheng, J. et al.,
Zhongguo Yixue Kexueyuan Xuebao
13:391 (1991).
Zheng, J. et al.,
Zhongguo Yixue Kexueyuan Xuebao
16:24 (1994).
BACKGROUND OF THE INVENTION
Immunosuppressive agents are widely used in the treatment of autoimmune disease and in treating or preventing transplantation rejection, including the treatment of graft-versus-host disease (GVHD), a condition in which transplanted marrow cells attack the recipient's cells. Common immunosuppressive agents include azathioprine, corticosteroids, cyclophosphamide, methotrexate, 6-mercaptopurine, vincristine, and cyclosporin A. In general, none of these drugs are completely effective, and most are limited by severe toxicity. For example, cyclosporin A, a widely used agent, is significantly toxic to the kidney. In addition, doses needed for effective treatment may increase the patient's susceptibility to infection by a variety of opportunistic invaders.
A number of compounds derived from the Chinese medicinal plant
Tripterygium wilfordii
(TW) have been identified as having immunosuppressive activity, e.g. in the treatment of autoimmune disease, and in treating or preventing transplantation rejection, including the treatment of graft-versus-host disease (GVHD), a condition in which transplanted marrow cells attack the recipient's cells. See, for example, coowned U.S. Pat. No. 6,150,539 (Triptolide prodrugs having high aqueous solubility), U.S. Pat. No. 5,962,516 (Immunosuppressive compounds and methods), U.S. Pat. No. 5,843,452 (Immunotherapy composition and method), U.S. Pat. No. 5,759,550 (Method for suppressing xenograft rejection), U.S. Pat. No. 5,663,335 (Immunosuppressive compounds and methods), and U.S. Pat. No. 5,648,376 (Immunosuppressant diterpene compound), and references cited therein. Such compounds have also been reported to show anticancer activity. See, for example, Kupchan et al., 1972, 1977, as well as copending and coowned U.S. application Ser. No. 09/766,156.
The administration and therapeutic effectiveness of these compounds have been limited, however, by their low water solubility. This problem has been addressed by formulating the compounds in mixtures of ethanol and polyethoxylated castor oil (e.g., “CREMOPHOR EL™”), allowing subsequent dilution in saline for intravenous administration. However, such formulations have suffered from high toxicity, due to the high concentration of solubilizing agent required to dissolve these compounds. For example, the ratio of solubilizing agent (ethanol plus “CREMOPHOR EL™”) to triptolide in such formulations is typically on the order of 1000:1 or greater, due to the poor solubility of triptolide (Morris, 1991; Morris et al., 1991). Standardization of dosage amounts is also more problematic with a suspension than with a solution.
It is therefore desirable to provide immunosuppressive compounds having comparatively low toxicity and improved water solubility. Ideally, such compounds would show immunosuppressive activity in their water soluble form, or would be convertible to an immunosuppressive form in vivo.
SUMMARY OF THE INVENTION
In one aspect, the invention provides compounds which are useful as prodrugs for immunosuppressive, anti-inflammatory and anticancer therapy. The compounds are derivatives of triptolide having hydrophilic substituents, represented by structures I-III, as shown and described below. The compounds possess greater water solubility than the non-derivatized parent compound, triptolide, and, in most cases, are effective to hydrolytically convert to the parent compound in vivo.
These and other objects and features of the invention will become more fully apparent when the following detailed description of the invention is read in conjunction with the accompanying drawings.
REFERENCES:
patent: 4005108 (1977-01-01), Kupchan et al.
patent: 5962516 (1999-10-01), Qi et al.
patent: 5972998 (1999-10-01), Jung et al.
patent: 6150539 (2000-11-01), Musser
patent: WO97/31921 (1997-09-01), None
Dai Dongcheng
Musser John H.
Yuan Hongwei
Gorthey LeeAnn
Perkins Coie LLP
Pharmagenesis, Inc.
Solola Taofiq
LandOfFree
Triptolide prodrugs having high aqueous solubility does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Triptolide prodrugs having high aqueous solubility, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Triptolide prodrugs having high aqueous solubility will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3075693